A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples